Inflammatory bowel disease continues to rise and cost, with global age standardized incidence increasing by 0.46% each year from 1990 to 2017 and the total average annual burden reaching USD 2,201 per person in 2017. In the US alone, IBD is estimated to cost about USD 21.9 billion per year and drive 1.3 million emergency room visits in 2015, even as many patients still wait 8 to 12 months for diagnosis. Let’s connect these gaps from delay and comorbidities to treatment access and real world outcomes.
Key Takeaways
- IBD incidence increased by 0.46% per year from 1990 to 2017 globally (age-standardized)
- USD 2,201 average global annual cost per person with IBD (2017, direct + indirect combined)
- A 2021 estimate put the US total (direct + indirect) annual cost of IBD at about USD 21.9 billion
- In the US, IBD-related ER visits were 1.3 million in 2015
- IBD is most common among adults aged 20–39 in the US (2016–2017 prevalence profile)
- 33.6% of people with IBD reported at least 1 comorbidity in a large US cross-sectional survey (2019)
- AbbVie reported USD 5.7 billion in Humira (adalimumab) global sales in 2019 (pre-biosimilar erosion baseline)
- In the UK, NHS spends about GBP 1 billion per year on biologic treatments for IBD
- In the US, TNF inhibitor therapy represented the largest share of biologic prescriptions for IBD (claims-based analysis)
- About 30% of patients with IBD fail to respond to initial anti-TNF therapy (review estimate)
- Long-term remission rates with biologic therapy vary, with clinical remission around 30–40% at 1 year in trials (meta-analysis ranges)
- Vaccination coverage among IBD patients is suboptimal; one survey found only 49% were up to date with influenza vaccination
- In a survey of IBD patients, 43% reported fear of side effects as a reason for delaying biologic therapy (patient-reported reasons)
- Therapy adherence rates in IBD commonly range around 70–80% in observational studies (systematic review)
- 20% of people with IBD experience symptoms that interfere with their work, education, or daily activities
IBD costs are soaring as incidence rises, delays persist, and treatment outcomes and adherence remain challenging.
Related reading
01 · Category
Economic Impact3 stats
01
IBD incidence increased by 0.46% per year from 1990 to 2017 globally (age-standardized)
02
USD 2,201 average global annual cost per person with IBD (2017, direct + indirect combined)
03
A 2021 estimate put the US total (direct + indirect) annual cost of IBD at about USD 21.9 billion
Interpretation
Economic Impact Interpretation
From 1990 to 2017, IBD incidence rose by 0.46% each year globally, and the economic impact is substantial with an estimated USD 2,201 average annual per-person cost in 2017 and an estimated USD 21.9 billion in US annual direct and indirect costs in 2021.
02 · Category
Healthcare Utilization7 stats
01
In the US, IBD-related ER visits were 1.3 million in 2015
02
IBD is most common among adults aged 20–39 in the US (2016–2017 prevalence profile)
03
33.6% of people with IBD reported at least 1 comorbidity in a large US cross-sectional survey (2019)
04
Over 25% of patients with IBD reported symptoms affecting work productivity in a 2018 survey
05
Mean time from symptom onset to IBD diagnosis was 8–12 months in a prospective cohort study (Europe)
06
Up to 37% of patients experience diagnostic delay beyond 12 months (systematic review figure)
07
US IBD patients had higher 30-day readmission rates than non-IBD patients (observed inpatient cohort comparison)
Interpretation
Healthcare Utilization Interpretation
For the healthcare utilization angle, the data show that IBD creates substantial acute and ongoing strain on services, with 1.3 million ER visits in the US in 2015 and diagnostic delays of over 12 months affecting up to 37% of patients, which likely contributes to higher 30-day readmission rates than non-IBD patients.
03 · Category
Market & Industry2 stats
01
AbbVie reported USD 5.7 billion in Humira (adalimumab) global sales in 2019 (pre-biosimilar erosion baseline)
02
In the UK, NHS spends about GBP 1 billion per year on biologic treatments for IBD
Interpretation
Market & Industry Interpretation
From a market and industry perspective, the scale of biologic spend is clear as Humira reached about USD 5.7 billion in global IBD related sales in 2019 before biosimilar erosion, while the UK NHS still allocates roughly GBP 1 billion each year to biologics for IBD.
04 · Category
Therapies & Outcomes11 stats
01
In the US, TNF inhibitor therapy represented the largest share of biologic prescriptions for IBD (claims-based analysis)
02
About 30% of patients with IBD fail to respond to initial anti-TNF therapy (review estimate)
03
Long-term remission rates with biologic therapy vary, with clinical remission around 30–40% at 1 year in trials (meta-analysis ranges)
04
Vedolizumab had week-52 clinical remission rates of about 50% in pivotal ulcerative colitis trials (reported efficacy)
05
Ustekinumab showed week-44 clinical remission rates of about 34% in Crohn’s disease maintenance results (trial data)
06
Risankizumab achieved week-52 clinical remission rates around 47% in moderate-to-severe Crohn’s disease (trial results)
07
Tofacitinib produced clinical response in about 60% of ulcerative colitis patients at week 8 in pivotal trials (trial efficacy)
08
Anti-TNF therapy is associated with reduced colectomy risk in ulcerative colitis (relative risk reduction estimated in meta-analysis)
09
Treat-to-Target strategies improve deep remission rates versus standard care (meta-analysis estimate of benefit)
10
Surgical resection is required in about 50% of Crohn’s disease patients within 10 years (cohort estimate)
11
In ulcerative colitis, about 25–30% of patients will require colectomy over 10 years (cohort estimate)
Interpretation
Therapies & Outcomes Interpretation
Across IBD therapies, the biggest outcomes signal is that biologic and targeted treatments can deliver meaningful remission for many patients but they do not reliably prevent progression, with anti TNF failing in about 30% at first response and long term measures showing roughly 25 to 30% of ulcerative colitis patients and about 50% of Crohn’s disease patients still needing surgery within 10 years.
05 · Category
Patient & Provider11 stats
01
Vaccination coverage among IBD patients is suboptimal; one survey found only 49% were up to date with influenza vaccination
02
In a survey of IBD patients, 43% reported fear of side effects as a reason for delaying biologic therapy (patient-reported reasons)
03
Therapy adherence rates in IBD commonly range around 70–80% in observational studies (systematic review)
04
Patient-reported quality of life is substantially impaired; IBD patients have worse utility scores than general population (EQ-5D comparisons)
05
In a cross-sectional study, 48% of IBD patients reported experiencing fatigue as a major symptom burden
06
Nearly 25% of IBD patients report clinically significant anxiety or depression symptoms (systematic review estimate)
07
Smoking increases risk of Crohn’s disease; active smokers have about 1.6–2.0x higher risk than never smokers (meta-analysis range)
08
Dietary fiber intake is associated with lower risk of Crohn’s disease in cohort studies; highest vs lowest quartile reduces risk (reported RR around 0.7)
09
In a randomized trial, structured patient education improved IBD knowledge scores by about 20 points on a standardized test (intervention effect)
10
A large US administrative study found gastroenterology follow-up within 3 months after IBD diagnosis in 62% of patients (care pattern)
11
In a UK audit, 71% of IBD patients received recommended thiopurine metabolite monitoring (clinical quality metric)
Interpretation
Patient & Provider Interpretation
From the patient and provider perspective, gaps in prevention and support are clear as influenza vaccination is up to date for only 49% and follow-up within 3 months occurs in just 62%, while therapy adherence sits around 70 to 80% and nearly 25% of patients report clinically significant anxiety or depression.
More related reading
06 · Category
Epidemiology4 stats
01
20% of people with IBD experience symptoms that interfere with their work, education, or daily activities
02
1.3 million IBD-related emergency department visits occurred in the US in 2015
03
3.1 million people in Europe were estimated to have IBD in 2017
04
The global prevalence of IBD increased from 35.6 million in 1990 to 53.1 million in 2017 (estimated)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, IBD has expanded substantially worldwide from 35.6 million people in 1990 to 53.1 million in 2017, and that rising burden is reflected in large health system impacts such as 1.3 million emergency department visits in the US in 2015.
07 · Category
Market Size4 stats
01
The US IBD biologics market was valued at about $7.4 billion in 2020
02
The global inflammatory bowel disease treatment market is forecast to reach about $43.9 billion by 2030
03
The global IBD market is expected to grow at a CAGR of about 6.5% from 2021 to 2030 (estimate)
04
The US IBD therapeutics market is projected to reach about $24.0 billion by 2030 (estimate)
Interpretation
Market Size Interpretation
The market size picture for IBD is set to expand rapidly, with the US IBD biologics market at about $7.4 billion in 2020 and the global market forecast reaching roughly $43.9 billion by 2030 as it grows at an estimated 6.5% CAGR from 2021 to 2030.
08 · Category
Industry Trends2 stats
01
By 2023, the EMA had authorized multiple biosimilars for infliximab, including CT-P13-related products (number of authorized biosimilars: at least 7)
02
In 2020, the FDA approved an IBD-related biologic or biosimilar in the US (number of approvals: 1)
Interpretation
Industry Trends Interpretation
In the industry trends for IBD, the EMA had authorized at least 7 biosimilars for infliximab by 2023 including CT P13 related products, showing accelerating competitive expansion, while the US saw just 1 FDA IBD biologic or biosimilar approval in 2020.
09 · Category
Access And Care1 stats
01
In the US, gastroenterology practice wait times for new patients with IBD were reported at a median of 28 days in 2022 (survey estimate)
Interpretation
Access And Care Interpretation
In the US, access to IBD care remains a challenge, with gastroenterology practice wait times for new patients averaging a median of 28 days in 2022.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Thomas Lindqvist. (2026, February 13). Ibd Statistics. Gitnux. https://gitnux.org/ibd-statistics
MLA
Thomas Lindqvist. "Ibd Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ibd-statistics.
Chicago
Thomas Lindqvist. 2026. "Ibd Statistics." Gitnux. https://gitnux.org/ibd-statistics.
Sources & references
45 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)